Grants and Contributions:
Title:
Regulatory strategy and plan to support commercialization strategy
Agreement Number:
955843
Agreement Value:
$50,000.00
Agreement Date:
Sep 1, 2020 - Mar 15, 2021
Description:
The project is to develop global regulatory strategy for therapeutics, in vitro diagnostics, natural health products, and laboratory research reagents of CCOA Therapeutics (CCOA). This strategy will allow CCOA to understand all regulatory requirements, costs, timelines, resources required, risks, areas to monitor, potential hurdles. This project is also to build a Quality Management System in CCOA and development of SOPs.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5B 1T8
Reference Number:
172-2020-2021-Q2-955843
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
780647129
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 15 days.
Amendment Date
Jan 26, 2021
Recipient's Operating Name:
CCOA Therapeutics Inc
Recipient's Legal Name:
CCOA Therapeutics Inc
Federal Riding Name:
Toronto Centre
Federal Riding Number:
35108
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: